Clinical trials: Hepatobiliary Diseases
Non-Alcoholic Fatty Liver Disease, NAFLD
SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver Disease
This study is a randomized, double-blind, placebo-controlled trial specifically designed to evaluate the preliminary feasibility, initial efficacy and safety of SGLT2 inhibitors for treating NAFLD in adolescents with obesity.
- Conditions
- Non-Alcoholic Fatty Liver Disease, NAFLD, Pediatric NAFLD
- Trial name
- SLIDE (NCT03867487)
- Testing
- Empagliflozin 10 MG
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Justin Ryder
Non Alcoholic Steatohepatitis
the Efficacy and Safety of Diosmin on Non-diabetic Patients With Non-alcoholic Steatohepatitis.
This is a randomized, controlled study evaluating diosmin tablets administered daily for 3 months. The purpose of the study is to evaluate the efficacy and safety of diosmin on non-diabetic patients with non-alcoholic…
- Trial name
- NCT05942547
- Testing
- Diosmin
- Where
- Egypt
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Tanta University
Non Alcoholic Fatty Liver Disease
Safety And Efficacy Study Of Orally Administered Epeleuton In Patients With NAFLD
The purpose of this randomised, double-blind, placebo-controlled, parallel group study is to assess the safety and efficacy of orally administered Epeleuton capsules versus placebo in the treatment of adult patients with Non…
- Trial name
- NCT02941549
- Testing
- Epeleuton
- Where
- 16 sites in Georgia, Ukraine and 1 more
- Volunteers
- 96 people
- Sponsor
- Afimmune
NASH - Nonalcoholic Steatohepatitis
Ascending Dose Study of HU6 in Healthy Volunteers
This is a single ascending dose trial in healthy volunteers. The study will be conducted in up to 7 cohorts. Upon review of the safety and PK data, it may be decided to expand the current cohort versus dose escalate to the next…
- Trial name
- NCT04463017
- Testing
- HU6
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Rivus Pharmaceuticals, Inc.
Overt, Sub-clinical
Association Between Overt and Sub-clinical Primary Hypothyroidism and Metabolic Dysfunction-Associated Steatoic Liver Disease in Non-Diabetic Patients
This study aims to estimate the prevalence of Metabolic dysfunction - associated Steatoic liver disease (MASLD) among adults with primary hypothyroidism (overt or sub-clinical 1ry hypothyroidism) and prevalence of MASLD in…
- Conditions
- Overt, Sub-clinical, Primary Hypothyroidism, Metabolic Dysfunction-Associated Steatoic Liver Disease
- Trial name
- NCT07603817
- Testing
- FibroScan, Thyroid Function Assessment
- Where
- Egypt
- Volunteers
- 200 people
- Sponsor
- Sohag University
Alcohol-related Liver Disease, Liver Diseases
Enhancing Alcohol Treatment Engagement in Associated Liver Disease (ALD) Patients
The purpose of this trial is to see if providing patients with alcohol-related liver disease with tailored alcohol use treatment options will increase engagement with treatment and correct possible misconceptions.
- Trial name
- ENGAGE-ALD (NCT06269510)
- Testing
- ENGAGE-ALD Application (APP), Treatment Facilitation bundle, Enhanced Usual Care
- Where
- United States
- Volunteers
- 268 people
- Sponsor
- Henry Ford Health System
Non-Alcoholic Fatty Liver Disease
Tocotrienol as a Treatment for Non-alcoholic Fatty Liver Disease
Vitamin E's potential in treating non-alcoholic fatty liver disease (NAFLD) is attributed to its antioxidant properties. While tocopherols have shown significant results in NAFLD management, the powerful properties of…
- Trial name
- NCT06596382
- Testing
- Tocotrienol rich-vitamin E
- Where
- Malaysia
- Volunteers
- 264 people
- Sponsor
- National University of Malaysia
Nonalcoholic Steatohepatitis (NASH) With Fibrosis
Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)
The primary objectives of this study are to evaluate the effect of Elafibranor treatment compared to placebo on 1) histological improvement and 2) all-cause mortality and liver-related outcomes in patients with nonalcoholic…
- Trial name
- RESOLVE-IT (NCT02704403)
- Testing
- Elafibranor
- Where
- 326 sites in United States, Argentina and 23 more
- Volunteers
- 2,157 people
- Sponsor
- Genfit
Glucose Metabolism, NAFLD (Nonalcoholic Fatty Liver Disease)
Measuring Amino Acid and Glucose Metabolism in Healthy Volunteers and NAFLD Patients Using Total-body PET
This observational study aims to quantify whole-body amino acid and glucose metabolism in healthy adults and in patients with non-alcoholic fatty liver disease (NAFLD) using total-body PET/CT.
- Trial name
- NCT07366710
- Testing
- 18F-FDG (oral), 18F-FDG (intravenous), 18F-FET (oral)
- Where
- Denmark
- Volunteers
- 36 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Alpha 1-antitrypsin Deficiency (AATD)
Natural Course and Molecular Basis of Alpha 1- Antitrypsin Deficiency-associated Liver Disease.
To define the course of AATD-associated liver disease. To use the obtained samples for biomedical research which includes: 1. Search for serum-based disease biomarkers and the associated molecular pathways. 2.
- Trial name
- NCT07639996
- Testing
- Multi-omic spatial analysis
- Volunteers
- 45 people
- Sponsor
- Assiut University
NASH - Nonalcoholic Steatohepatitis
Effects of Plant Sterols and Stanols on Liver Inflammation
This study is a randomized, placebo-controlled, double blinded pilot study to assess the effect of consuming plant sterol or plant stanol esters (3 grams/day) for 6 months on ALT concentrations in subjects with elevated ALT…
- Trial name
- NCT05037890
- Testing
- Margarine
- Where
- Netherlands
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Maastricht University Medical Center
Non-alcoholic Steatohepatitis
Clinical Effects of New Approach on Patients With Non-alcoholic Steatohepatitis
This study aims to evaluate and compare the protective outcomes of using Rosuvastatin, Vitamin E, and N-acetyl cysteine in Egyptian patients with NASH.
- Trial name
- NCT06105060
- Testing
- Rosuvastatin 20mg
- Where
- Egypt
- Volunteers
- 175 people
- Sponsor
- Beni-Suef University
Hepatorenal Syndrome
Comparison of Terlipressin Versus Octreotide in Patients With Hepatorenal Syndrome
Hepatorenal syndrome is a serious complication of advanced liver disease in which kidney function rapidly worsens and can lead to life-threatening illness.
- Trial name
- NCT07460908
- Testing
- terlipressin, Octreotide (drug)
- Where
- Pakistan
- Volunteers
- 60 people
- Sponsor
- Lahore General Hospital
Non-alcoholic Fatty Liver Disease
Alternation of Non-alcoholic Fatty Liver Disease (NAFLD) and Cardiovascular Risks After Liftestyle Modification: A Ultrasound Attenuation Imaging-Based Study
The prevalence of obesity has significantly increased over the last few decades. The excessive fat accumulation in undesired areas in obese patients may lead to various complications, such as cardiovascular diseases and…
- Trial name
- NCT04440540
- Testing
- Dietitian led life style modification intervention, Conventional care (control)
- Where
- Hong Kong
- Volunteers
- 10 people
- Sponsor
- Chinese University of Hong Kong
Chronic Liver Disease
Mobile Chat Messaging for Alcohol Reduction in Patients With Chronic Liver Diseases
The goal of this pilot randomized controlled trial is to evaluate the trial feasibility and acceptability of mobile chat messaging for reducing alcohol use among patients with chronic liver diseases.
- Trial name
- NCT06587568
- Testing
- Mobile chat messaging, Screening, brief intervention and referral to treatment
- Where
- Hong Kong
- Volunteers
- 106 people
- Sponsor
- The University of Hong Kong
Cholestasis, Liver Disease
Enteral Fish Oil is Superior to Ursodeoxycholic Acid (UDCA) and Placebo for the Treatment of Cholestasis in Infants
To investigate the effect of enteral fish oil and UDCA on the time of cholestasis resolution and other markers of parenteral nutrition-associated liver disease.
- Trial name
- NCT02420496
- Testing
- Enteral fish oil, Ursodeoxycholic Acid
- Where
- United States
- Sponsor
- The University of Texas Health Science Center at San Antonio
Non-alcoholic Steatohepatitis, Non-Alcoholic Fatty Liver Disease
Nutritional Cognitive Behavioral Therapy Feasibility Study in NAFLD and NASH
This single arm interventional cohort study is designed to explore the feasibility of using BT-NCBT-00x to improve liver fat, inflammation, and stiffness in patients diagnosed with NAFLD or NASH over a 3 month intervention.
- Conditions
- Non-alcoholic Steatohepatitis, Non-Alcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver
- Trial name
- NCT05357248
- Testing
- BT-NCBT-00X
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- Better Therapeutics
Alcoholic Hepatitis
BActeriophages To Treat Liver Disease Eliminating Harmful Bacteria (BATTLE)
Alcoholic hepatitis is a disease with a high mortality rate with few treatment options improving survival. Recently certain bacterial strains has been correlated to survival in patients with alcoholic hepatitis.
- Trial name
- BATTLE (NCT05618418)
- Testing
- No intervention
- Where
- Denmark
- Volunteers
- 30 people
- Sponsor
- Copenhagen University Hospital, Hvidovre
Non Alcoholic Fatty Liver Disease, Type2 Diabetes Mellitus
Effect of Dulaglutide on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
This D-LIFT (Effect of dulaglutide on Liver Fat) trial is an investigator initiated, prospective, open label, randomized clinical study to examine the effect of dulaglutide 0.75 mg subcutaneously weekly for 4 weeks, followed by…
- Trial name
- D-LIFT (NCT03590626)
- Testing
- Dulaglutide
- Where
- India
- Volunteers
- 60 people
- Sponsor
- Medanta, The Medicity, India
Liver Cirrhosis, Cognitive Dysfunction
The Liver Cirrhosis Cognitive Decline Scale (LiCCoS)
The goal of this observational study is to develop and test a new questionnaire called the Liver Cirrhosis Cognitive Decline Scale (LiCCoS) for adults with liver cirrhosis.
- Conditions
- Liver Cirrhosis, Cognitive Dysfunction, Hepatic Encephalopathy, Neurocognitive Disorders
- Trial name
- LiCCoS (NCT07418008)
- Where
- India
- Volunteers
- 230 people
- Sponsor
- University of Malaya